Stocks and Investing
Stocks and Investing
Mon, December 5, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Sun, December 4, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, December 2, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Alec Stranahan Downgraded (YMAB) to Hold and Decreased Target to $5 on, Dec 2nd, 2022
Alec Stranahan of B of A Securities, Downgraded "Y-mAbs Therapeutics, Inc." (YMAB) to Hold and Decreased Target from $23 to $5 on, Dec 2nd, 2022.
Alec has made no other calls on YMAB in the last 4 months.
There are 6 other peers that have a rating on YMAB. Out of the 6 peers that are also analyzing YMAB, 2 agree with Alec's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $8 on, Monday, October 31st, 2022
- David Nierengarten of "Wedbush" Downgraded from Buy to Hold and Held Target at $6 on, Monday, October 31st, 2022
These are the ratings of the 4 analyists that currently disagree with Alec
- Etzer Darout of "BMO Capital" Maintained at Buy with Decreased Target to $12 on, Tuesday, November 1st, 2022
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $19 on, Monday, October 31st, 2022
- Tessa Romero of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $7 on, Monday, October 31st, 2022
- William Maughan of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $27 on, Monday, October 31st, 2022
Contributing Sources